Linvoseltamab vs Vonsetamig

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline

Linvoseltamab

Marketed by Regeneron Pharmaceuticals

Approved in Multiple Myelomabispecific antibody (T-cell engager)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT06376526 (registry estimate)

No aligned efficacy figure on record for this race.

Vonsetamig

Developed by Regeneron Pharmaceuticals

Phase 1/2 in Multiple Myeloma
Weak signal

NCT04083534 · Phase 1/2 · completed

This early-stage study gave REGN5459 to 43 people with relapsed or refractory multiple myeloma across a range of doses, with no randomisation, no masking and no comparison group. Its primary measure was dose-limiting toxicity: one such event occurred, a grade 3 drop in blood oxygen at the highest 900 mg dose, the maximum tolerated dose was not reached, and 480 mg was chosen for later study. A study of this shape shows which doses are tolerated, not whether the drug works better than an alternative.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period (Up to 35 Days); Incidence and severity of treatment-emergent adverse events (TEAEs) during REGN5459 treatment period (Up to 12 Weeks After the Last Dose); Incidence and severity of adverse events of special interest (AESI) with REGN5459 treatment period (Up to 12 Weeks After the Last Dose); Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria (Up to Approximately 104 Weeks): Dose-limiting toxicity incidence across the dose-escalation range (3-900 mg): 1 DLT observed in 43 enrolled patients, at the 900 mg dose level (grade 3 hypoxia); maximum tolerated dose not reached, 480 mg selected as the recommended phase 2 dose. (not_applicable)

Result source: NCT04083534

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLinvoseltamabVonsetamig
PFS, median—Trial running · NCT06932562—Not reported
OS, median—Trial running · NCT06932562—Not reported
ORR—Trial running · NCT06932562—Not reported
VGPR or better—Trial running · NCT06932562—Not reported
MRD negativity—Trial running · NCT06932562—Not reported

PFS, median

Linvoseltamab
—Trial running · NCT06932562
Vonsetamig
—Not reported

OS, median

Linvoseltamab
—Trial running · NCT06932562
Vonsetamig
—Not reported

ORR

Linvoseltamab
—Trial running · NCT06932562
Vonsetamig
—Not reported

VGPR or better

Linvoseltamab
—Trial running · NCT06932562
Vonsetamig
—Not reported

MRD negativity

Linvoseltamab
—Trial running · NCT06932562
Vonsetamig
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Linvoseltamab: no structured comparison results are available for Multiple Myeloma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Vonsetamig
Dose-limiting toxicity incidence across the dose-escalation range (3-900 mg): 1 DLT observed in 43 enrolled patients, at the 900 mg dose level (grade 3 hypoxia); maximum tolerated dose not reached, 480 mg selected as the recommended phase 2 dose. NCT04083534 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linvoseltamab's landscape · Vonsetamig's landscape